nCounter® Canine IO Panel

Helping Your Research

Covering hundreds of genes involved in the immune response of canines to immuno-oncology therapeutics and designed with experts in canine comparative oncology, the nCounter Canine IO Panel is the only gene expression panel built to study the tumor and immune response to IO treatments in dogs. The panel takes advantage of tumor-specific coverage for the most common canine cancers to enable researchers to share data and access enhanced statistical power, potentially improving clinical trial success by translating findings from the treatment of spontaneous canine cancer to humans.

Product Highlights:

  • Profile 800 genes across 47 annotated pathways involved in canine immune response to IO treatments
  • Overlapping content with NanoString’s Human PanCancer IO 360 and PanCancer Immune Profiling Panels provides a suite of panels for comparative studies
  • PanCancer coverage with tumor specific content for top canine cancers including Melanoma, Osteosarcoma, Lymphoma, Urothelial Carcinoma, and Glioblastoma
  • Easy to use nCounter system provides data in 24 hours with less than 30 minutes hands on time and simple data analysis
  • Easy data sharing and collaboration with a common set of genes and a panel standard
Medallion for Canine IO panel

How It Works

The Canine IO Panel was created through a collaboration between NanoString and the Canine Consortia, a consortium of researchers from multiple prestigious institutes, including the University of Alabama, the University of California- DavisColorado State University, the University of Minnesota, the University of PennsylvaniaTufts, and Freie Univ. Berlin. The Canine Consortia includes key members of the Cancer Moonshot Consortium, which aims to:

  • Promote the development of cancer immunotherapies for several common human cancers — glioma, osteosarcoma, melanoma, and lymphoma
  • Foster a collaborative immunotherapy network for comparative medicine

Tumor Specific Coverage for Top Canine Cancers

Included within the Canine IO Panel content are tumor specific targets for five of the top canine cancers, also common in humans:








Urothelial Carcinoma



Panel Selection Tool

Find the gene expression panel for your research with Panel Pro

Find Your Panel

Product Information

Signatures/ Pathways
Catalog Information
Signatures/ Pathways

The nCounter Canine IO Panel enables researchers to explore canine immune response to immune-oncology treatments.

Catalog Information

Related Resources

See All Resources
Product Bulletin Canine IO Panel – Product Bulletin
Blog Post NanoString Proudly Introduces the new nCounter® Canine IO Panel.
Blog Post A “Tail” of Two Species: New Canine Immuno-Oncology Research Offering
Event A Tail of Two Species: Canine Comparative Oncology Webinar and Panel Discussion
Poster Multi-National, Multi-Center Collaboration to Develop a Novel Gene Expression Tool for Comparative Translational IO (AACR 2021)
Manual/Instructions NanoU Training Videos

Selected Panel References

View All Publications

Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma

Histiocytic sarcoma (HS) is a rare and aggressive tumor in humans with no universally agreed standard of care therapy. Spontaneous canine HS exhibits increased prevalence in specific breeds, shares key genetic and biologic similarities with the human disease, and occurs in an immunocompetent setting.

Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy

Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming. However, barriers have arisen in the effective translation of NK cells to the clinic, in part because of critical species differences between mice and humans.

Top 10 Challenges in Cancer Immunotherapy

Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress.

Gene expression markers of Tumor Infiltrating Leukocytes

Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the intratumoral abundance of various immune cell populations with gene expression.

Whole genome sequencing of canids reveals genomic regions under selection and variants influencing morphology

Domestic dog breeds are characterized by an unrivaled diversity of morphologic traits and breed-associated behaviors resulting from human selective pressures. To identify the genetic underpinnings of such traits, we analyze 722 canine whole genome sequences (WGS), documenting over 91 million single nucleotide and small indels, creating a large catalog of genomic variation for a companion animal species.

Request a Quote

Contact our helpful experts and we’ll be in touch soon.